U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06823427) titled '9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma' on Jan. 13.
Brief Summary: This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced setting.
Study Start Date: Jan. 17
Study Type: INTERVENTIONAL
Condition:
Urothelial Carcinoma
Urothelial Carcinoma Bladder
Urothelial Carcinoma Recurrent
Urothelial Carcinoma of the Renal Pelvis and Ureter
Intervention:
DRUG: 9MW2821
a nectin-4 ADC with MMAE payload
DRUG: Toripal...